Trial Profile
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Fadraciclib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Cyclacel Pharmaceuticals
- 24 Jan 2024 Status changed from active, no longer recruiting to completed.
- 22 Apr 2022 Planned End Date changed from 15 May 2020 to 1 Jul 2023.
- 22 Apr 2022 Planned primary completion date changed from 15 Jan 2020 to 1 Jan 2023.